ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,026.99
      0.23%
      US Tech 100
      20,976.00
      -0.32%
      Dow Jones
      43,634.09
      0.47%
      Brent Oil
      74.425
      0.43%
      Bitcoin
      94,935.88
      -1.39%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Agenus Inc (AGEN)

      7. Agenus Inc (AGEN) News

      Agenus Inc

      Agenus Inc (AGEN)

      NASDAQ
      3.21
      -0.11
      ( -3.31% )
      Updated: 12:03:50
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      AGEN News

      Official News Only

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 18 2025
      AGEN (-3.31%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      February 10 2025
      AGEN (-3.31%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 04 2025
      AGEN (-3.31%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 28 2025
      AGEN (-3.31%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 02 2025
      AGEN (-3.31%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      January 02 2025
      AGEN (-3.31%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      December 05 2024
      AGEN (-3.31%)

      AGEN Discussion

      View Posts
      Monksdream Monksdream 2 months ago
      AGEN under $3
      👍️0
      Monksdream Monksdream 4 months ago
      AGEN under $5
      👍️0
      Monksdream Monksdream 6 months ago
      AGEN new 52 week low
      👍 1
      Monksdream Monksdream 7 months ago
      AGEN under $7
      👍️0
      ErnieBilco ErnieBilco 7 months ago
      I tossed a couple of coins in the fountain at $7 wishing for 50% or better
      👍️0
      DP1011 DP1011 8 months ago
      Up here. Keep on going!!!
      👍️0
      jondoeuk jondoeuk 10 months ago
      I expect more dilution is on the way after the R/S. Unless they sell non-strategic assets, which is hardly a sustainable business practice.
      👍️0
      jondoeuk jondoeuk 11 months ago
      The co-founder/CEO/Chairman has been for 20+ years pumping the company, telling stories and making promises, all the while getting rich off retail.
      👍️ 1
      jondoeuk jondoeuk 11 months ago
      They are proposing a R/S at a ratio of 1-for-20 https://finance.yahoo.com/news/why-agenus-stock-plummeted-nearly-233805990.html
      👍️0
      Paullee Paullee 1 year ago
      where did you see that ??????
      👍️0
      TrendTrade2016 TrendTrade2016 1 year ago
      ALL OUT...REVERSE SPLIT ANNOUNCEMENT
      👍️0
      TrendTrade2016 TrendTrade2016 1 year ago
      AGEN SMALL GAPPER AND ON TARGET TO 1.04
      👍️0
      DP1011 DP1011 1 year ago
      Interesting, would be nice to see this back over a dollar.
      👍️0
      Stumblebum Stumblebum 1 year ago
      Something is cooking …..last week good upward movement and picked up volume 😊
      👍️0
      TrendTrade2016 TrendTrade2016 1 year ago
      AGEN POPPING HARD TO 1.04
      👍️0
      axelvento axelvento 1 year ago
      A Biologics License Application (BLA) is expected to be submitted to the FDA for metastatic colorectal cancer (CRC) in mid-2024.

      Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy

      Who knows what does the future hold$$$$$$$
      👍️0
      Denzel-72 Denzel-72 1 year ago
      R/S is coming … money down the drain
      👍️0
      Monksdream Monksdream 1 year ago
      AGEN new 52 week low
      👍️0
      TommyBoyTrader9460 TommyBoyTrader9460 1 year ago
      $AGEN
      https://x.com/hannahadad8890/status/1741101133777486197?s=61
      👍️0
      TommyBoyTrader9460 TommyBoyTrader9460 1 year ago
      $AGEN
      https://x.com/hannahadad8890/status/1739966219229258048?s=61
      👍️0
      Doktornolittle Doktornolittle 1 year ago
      Admin(s) please erase my post # 1170. I don't think the issues were the fault of B. Riley or ASCO... . Maybe, but it is unclear and not worth having the negativity there for posterity.
      👍️0
      Monksdream Monksdream 1 year ago
      AGEN new 52 week low
      👍️0
      Monksdream Monksdream 1 year ago
      AGEN new 52 week low
      👍️0
      Monksdream Monksdream 1 year ago
      AGEN new 52 week low

      👍️0
      Monksdream Monksdream 1 year ago
      AGEN new 52 week low
      👍️0
      Doktornolittle Doktornolittle 2 years ago
      ... B.Riley psswd is in immediate registration confirmation email. That may not be unusual, but the email subject line gives no indication that it contains a psswd. It gives a warm and fuzzy that your registration did go through, so the reader is not compelled to open the email. The reader already knows they registered and the reader does not yet know that they are going to have to login with a password. May be the usual way to do this, but I don't think it is a good way.

      As for ASCO GI. Some say the abstracts were embargoed since late-breaking. Maybe so, but why then did the ASCO website instruct me to login to view the abstract. This is with the abstract already located. This is on the abstract page, which only contains the header at that point. Causes confusion.
      👍️0
      Doktornolittle Doktornolittle 2 years ago
      B Riley would not allow me to view the recent webcast. ASCO would not allow me to view the recently "released: Abstracts. No PR from the company. This while Yhoo Finance is so controlled and filtered since the recent takeover that no light escapes there either.

      If you had a similar experience, please message me and we can join forces for a complaint to the SEC.

      More detail:
      B Riley has no contact other than their private email system which does not work.
      ASCO: Found the abstracts, but they told me that I had to log in to view the abstract beyond the header and authors. I spent 12 hours trying to do that. After many dead end phone calls and emails, I finally got them to allow me to log in. Went back to the abstract and now they tell me, you don't have access to the abstract. A slightly different message than when I was not logged in, but still no access.

      I videotaped my efforts to access the webcast and abstracts. I suggest you do the same if you have problems like this in the future.

      These are SEC violations.

      Where is the SEC on these things? I suspect they could care less, but I want to find out.
      👍️0
      Doktornolittle Doktornolittle 2 years ago
      SITC Oral Presentation on BOT w/wo BAL tomorrow with about a thousand authors. It is a brief presentation, but there are only 4 such on schedule and they are the last notes of the entire SITC session. It is likely that everybody at SITC who can get to these final presentations will be there. I am no technical expert in these matters, but I am confident that BOT is a big deal for a couple of reasons beyond the data. 1) In a brief presentation after ASCO, there were major league Cancer experts discussing the presented results. Those experts were truly impressed with this activity against cold tumors. I have seen phony looking presentations by small biotech companies, and this was not that. Of that I am certain and will listen to nobody else's opinion about it. 2) Agenus has been touting BOT for years now. They knew from the beginning that they had something very special. For me it is not a great leap of faith to expect big things from BOT w/wo BAL. No posts here in almost a year. None for months at alter forum IV, and alter other forum just went through a huge change. Suddenly no new posts in the last 24 hours in the middle of SITC? I don't thinks so. So far, I give the facelift at hooya a big thumbs down. This is it guys. Your new home.
      👍️ 1
      stockguard stockguard 3 years ago
      AGEN Agenus initiated with a Buy at H.C. Wainwright
      H.C. Wainwright analyst Michael King initiated coverage of Agenus with a Buy rating and $12 price target. The company has developed a broad portfolio of promising antibodies and bispecifics covering many validated targets in immuno-oncology, King tells investors in a research note. The company has "struck multiple lucrative development agreements with some of the industry's leading oncology players," adds the analyst.
      👍️0
      north40000 north40000 3 years ago
      $11 from $12. Buy rating. Analyst has been switching back and forth between $11 and $12. November date on last PT, per GOOGL search.
      👍️0
      investtemp investtemp 3 years ago
      what was the B Riley target price?
      👍️0
      stockguard stockguard 3 years ago
      B. Riley bullish on Novavax, Agenus amid Omicron spread.
      B. Riley analyst Mayank Mamtani reiterates his sector-level view of the need for at least annual vaccine boosters and there being a durable COVID vaccine market, sharing many of the attributes with an expanding flu market that has been clearly rewarding differentiated vaccine solutions. The analyst views sustenance of multiple vaccine modalities prevailing over an "mRNA takes all" viewpoint. Mamtani has a Buy rating and a price target of $305 on Novavax (NVAX) as Omicron variant-specific development preparedness and COV-Boost data reiterate robust positioning in global, durable COVID-19, and flu markets. The analyst also has a Buy rating and a price target on Agenus (AGEN) as he believes under-the-radar SaponiQx's adjuvant is poised to play a meaningful role in strong expected protein subunit vaccine demand. He keeps a Neutral rating on Vaxart (VXRT), calling it one of the few "investable" COVID-19 vaccine pipeline programs directly tackling the transmission issue.
      👍️0
      stockguard stockguard 3 years ago
      New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
      https://finance.yahoo.com/news/agenus-subsidiary-saponiqx-builds-innovative-113000784.html
      👍️0
      stockguard stockguard 3 years ago
      Will not be in the money until it hits their price, no biggie on this small fry:
      SEC Form S-3ASR filed by Agenus Inc.
      https://quantisnow.com/insight/2002956?s=s



      👍️0
      pipette pipette 3 years ago
      There was an article in Oct 26 did u get that one? Most trading platforms have news with their tickers too.
      👍️0
      malice1 malice1 3 years ago
      China just shut down yahoo and aol. I was on the Yahoo Agen Board. Can anyone keep me updated on any significant news?
      👍️0
      Jnk Jnk 3 years ago
      Got it!
      👍️0
      stockguard stockguard 3 years ago
      Either way i`m only focusing on 1181 now and the cash they have on the books to see it through. Market was overly fixated on Bali in cervical which was small niche as even Management suggested.
      👍️0
      Jnk Jnk 3 years ago
      Well I just bought a bunch more shares!! Hope it pays out!!
      👍️0
      stockguard stockguard 3 years ago
      UPDATE: Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
      https://www.fiercebiotech.com/biotech/agenus-withdraws-cervical-cancer-application-for-balstilimab-after-fda-fully-authorizes
      👍️0
      stockguard stockguard 3 years ago
      Agenus calls out FDA for playing favorites with Merck, pulls cervical cancer BLA at agency's request
      https://endpts.com/agenus-calls-out-fda-for-playing-favorites-as-it-pulls-cervical-cancer-bla-at-agencys-request/
      👍️0
      malice1 malice1 3 years ago
      longboarder have any idea what happened the last two days?
      👍️0
      longboarder7892 longboarder7892 3 years ago
      Thank you Dr. Hidalgo for all that you have done here with AGEN in just a few months we went from 2.50 to almost 6.50 and will be helping save lives. I hope your work will do the same for my other company that you are on the board of and the PI of their trial. AGEN is looking great with the BMY investment... mmmm

      Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
      Bristol-Myers Squibb Company (NYSE:BMY) and Agenus Inc. (NASDAQ:AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus' proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective.
      👍️0
      conix conix 4 years ago
      AGEN Chart

      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $AGEN Video Chart 05-18-2021 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      JohnLocke101 JohnLocke101 4 years ago
      Bristol Myers bets big on anti-TIGIT bispecific from Agenus in a partnership worth $1.5B+
      👍️0
      iancnyc iancnyc 4 years ago
      thank god i heard on
      look at that!!!
      👍️0
      moonurneighbor moonurneighbor 4 years ago
      Great news!
      👍️0
      JohnLocke101 JohnLocke101 4 years ago
      Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
      👍️0
      iancnyc iancnyc 4 years ago
      what’s going on with this Turd today?
      👍️0

      Your Recent History

      NASDAQ
      AGEN
      Agenus
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads